GLP-1 drugs like Wegovy, Ozempic, Trulicity, and more are generating a lot of buzz for their effectiveness in weight loss and diabetes management. We’ll break down what you need to know about Wegovy and Ozempic and how Medicare Part D fit into the picture.
What GLP-1s are covered by Medicare?
Under formal rules, Medicare is legally prohibited from covering weight loss medications. However, it can cover medications for other approved medical uses like diabetes and heart disease. GLP-1s drugs would be covered under Medicare Part D or Medicare Advantage (MA) plans, not Medicare Part B because it’s a self-administered medication. And Medicare Part D and MA plans cover Ozempic for type 2 diabetes treatment, but your doctor must prescribe it specifically for that to be eligible.
On the other hand, Wegovy’s recent FDA approval for reducing the risk of heart attack, stroke, or death in adults with overweight or obesity and cardiovascular disease has opened the door for Medicare coverage. This is significant because, based on 2020 data, this approved use could make approximately 3.6 million Medicare beneficiaries eligible for Wegovy coverage.
However, a brand-new pilot program starting in July 2026 is completely rewriting these rules for beneficiaries with obesity.
The July 2026 game-changer: The Medicare GLP-1 bridge
Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching a temporary pilot program called the Medicare GLP-1 Bridge. Running through December 31, 2027, this 18-month demonstration program allows eligible Medicare Part D and Medicare Advantage members to access select GLP-1 weight-loss medications for a flat $50 monthly copay. This is a historic shift, marking the first time Medicare will provide a direct pathway to coverage for obesity management.
Which GLP-1 Drugs are included in the Bridge Program?
It is important to note that the GLP-1 Bridge does not apply to every drug on the market. It specifically targets medications FDA-approved for weight loss, while leaving standard diabetes medications under regular Part D rules. Under this program, Medicare does cover Ozempic, Wegovy, and others.
| Medication | Primary FDA Approval | Covered Under Regular Part D? | Covered Under GLP-1 Bridge (July 2026)? |
| Wegovy (semaglutide) | Weight Loss / Cardio Risk | Only for reducing severe cardiovascular risk | Yes (All formulations) |
| Zepbound (tirzepatide) | Weight Loss | No | Yes (KwikPen formulation only) |
| Foundayo (oral semaglutide) | Weight Loss | No | Yes (All formulations) |
| Ozempic / Mounjaro | Type 2 Diabetes | Yes (Strictly for Type 2 Diabetes) | No |
To qualify for the Bridge program, you must be enrolled in a Medicare Part D plan (or a Medicare Advantage plan with drug coverage) and meet specific medical criteria. Your doctor must submit a prior authorization request verifying that you fall into one of three clinical tiers:
- Tier 1: A Body Mass Index (BMI) of 35 or higher (no other health conditions required).
- Tier 2: A BMI of 30 or higher, plus at least one comorbid condition such as heart failure, uncontrolled high blood pressure, or chronic kidney disease.
- Tier 3: A BMI of 27 or higher, plus pre-diabetes, a history of a heart attack or stroke, or peripheral artery disease.
How much do GLP-1 drugs cost with Medicare Part D?
As of this writing, Wegovy is listed at $1,300 per month. Even with Part D or MA coverage, you could face substantial out-of-pocket costs. Coinsurance may require you to pay 25-33% of the drug cost, which could amount to $325-$430 per month (according to the list price above). While the new out-of-pocket maximums in 2024 and 2025 offer some relief, even the $2,000 limit can still pose a financial burden for many beneficiaries.
Furthermore, some Medicare plans may require prior authorization for these kinds of drugs, potentially leading to delays or even denial of coverage. Note: How much beneficiaries pay out of pocket will depend on the plan and insurer as Part D plans are managed by private insurers. Fortunately, for those who qualify for the new July 2026 Bridge program, that monthly cost drops to a predictable $50—though there is a catch regarding how that money applies to your deductible
Because this program is a pilot project, it comes with a few unique catches that you should warn your readers about:
- It Operates Outside Part D Rules: Even though beneficiaries must have Part D to qualify, the program is processed externally (managed by Humana as a central claims processor).
- The Cost Cap Catch: The $50 monthly copay does not count toward a beneficiary’s standard annual Part D out-of-pocket maximum.
- No Low-Income Subsidies: For those who usually qualify for Extra Help or Low-Income Subsidies (LIS), those protections do not apply to the Bridge program—meaning the copay remains a flat $50 for everyone.
Taking action: Steps to explore coverage
If you’re considering Wegovy or Ozempic, it’s crucial to be proactive. Talk to your doctor to determine if these medications are right for you and if you meet the criteria for Medicare coverage. Contact your prescription plan provider to confirm their formulary status and understand your potential out-of-pocket costs. Don’t hesitate to explore assistance programs, such as manufacturer discounts or patient assistance programs, that could help make these treatments more affordable.
The landscape of Medicare coverage for GLP-1 medications is constantly evolving. Stay informed about the latest changes and advocate for affordable access to these potentially life-changing treatments.
*Disclaimer:
The information provided in this blog post is intended for general informational purposes only and does not constitute medical advice. It is not a substitute for professional medical consultation or treatment. Always consult with a qualified healthcare provider for any questions you may have regarding a medical condition.
United Medicare Advisors does not endorse or recommend any specific products, treatments, or procedures mentioned in this article. Reliance on any information provided in this blog post is solely at your own risk. We encourage you to discuss any health concerns or questions with your doctor before making any decisions about your health or treatment.
